Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Gelesis Holdings, Inc.

Gelesis’ Oral Treatment for Weight Management Showed Real-World Effectiveness in New Data Presented at the American Diabetes Association’s Annual Conference
From Gelesis Holdings, Inc.
Via Business Wire
Gelesis Reports Fourth Quarter and Full Year 2022 Results
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Gelesis to Participate in the 25th Annual ICR Conference
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Gelesis Reports Upcoming Participation in Wolfe Research’s Annual Consumer Growth Conference
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Gelesis Receives Notice of NYSE Market Capitalization Listing Rule Non-Compliance
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Gelesis Reports Third Quarter 2022 Results
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Gelesis Receives Notice of NYSE Trading Share Price Listing Rule Non-Compliance
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to Prebiotics
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis’ Oral Hydrogel Treatment GS200 at Obesity Week
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic Syndrome
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Gelesis Reports Second Quarter 2022 Results
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Gelesis to Report Second Quarter 2022 Financial Results on August 15, 2022
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Gelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Over the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New Study
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis’ Proprietary Hydrogel
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Gelesis to Participate in Upcoming Investor Conferences
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Gelesis Reports First Quarter 2022 Results
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Clinical Data Presented at the European Congress on Obesity 2022 Demonstrates Weight Loss With GS200 in Adults With Prediabetes and Type 2 Diabetes
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Gelesis’ Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New Study
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Gelesis® Reports Fiscal Year 2021 Results and Fiscal Year 2022 Financial Outlook
From Gelesis Holdings, Inc.
Via Business Wire
Tickers GLS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.